所有图片(1)

文件

Y0001511

格列本脲

Name: 格列本脲
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

所有图片(1)

别名:

5-氯-N-[4-(环己基脲磺酰)苯乙基]-2-甲氧基苯甲酰胺, N-对[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰基-N′-环己基脲, 格列本脲

经验公式（希尔记法）:

C₂₃H₂₈ClN₃O₅S

CAS号:

10238-21-8

分子量:

494.00

MDL编号:

MFCD00056625

PubChem化学物质编号:

329831466

NACRES:

NA.24

等级

pharmaceutical primary standard

API family

glibenclamide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES string

COc1ccc(Cl)cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3

InChI

1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)

InChI key

ZNNLBTZKUZBEKO-UHFFFAOYSA-N

Gene Information

human ... ABCC8(6833) , KCNJ11(3767)

正在寻找类似产品? Visit 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Glibenclamide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

1295527

BP237

Methyl N-4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulfonylcarbamate, British Pharmacopoeia (BP) Reference Standard

BP071

4-[2-(5-氯-2-甲氧基苯甲酰氨基)乙基]苯磺酰胺, British Pharmacopoeia (BP) Reference Standard

PHR2414

危险声明

H413

预防措施声明

P273 - P501

危险分类

Aquatic Chronic 4

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

如何查找产品货号

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503

货号

25G

包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务寻求帮助

如何查找COA批号

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。
如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。
如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Effects of glyburide on carbohydrate metabolism and insulin action in the liver.

J F Caro

The American journal of medicine, 89(2A), 17S-25S (1990-08-20)

Increased hepatic glucose production is responsible for fasting hyperglycemia in type II diabetes. Insulin resistance is the key in this process because of the inability of insulin to suppress hepatic glucose production, thereby allowing an unopposed glucagon effect. Glyburide, one

Glyburide-induced cholestatic hepatitis and liver failure. Case-report and review of the literature.

J P van Basten et al.

The Netherlands journal of medicine, 40(5-6), 305-307 (1992-06-01)

As sulphonylurea derivatives are used ubiquitously, the possibility that they may cause liver disease deserves attention. In contrast to the known pattern of reversible parenchymal liver disease due to sulphonylurea derivatives, we describe a fatal case of glyburide-induced cholestatic hepatitis

Granulomatous hepatitis associated with glyburide.

D Saw et al.

Digestive diseases and sciences, 41(2), 322-325 (1996-02-01)

A wide variety of diseases and injuries can cause granulomatous hepatitis, and drug-induced granulomatous hepatitis is a well-described entity. Sulfonylurea derivatives, which are commonly used oral hypoglycemic agents in the treatment of non-insulin-dependent diabetes mellitus, have been implicated in liver

Intervention to decrease glyburide use in elderly patients with renal insufficiency.

Sherrie L Aspinall et al.

The American journal of geriatric pharmacotherapy, 9(1), 58-68 (2011-04-05)

The objectives of this study were to describe changes in glyburide prescribing in cohorts that were and were not targeted by a risk reduction project, assess factors associated with glyburide discontinuation, and evaluate changes in glycated hemoglobin (ie, HbA(1c)) levels

Self-nanoemulsifying performance of two grades of Lauroglycol (Lauroglycol-90 and Lauroglycol-FCC) in the presence of mixed nonionic surfactants.

Faiyaz Shakeel et al.

Pharmaceutical development and technology, 19(7), 799-805 (2013-08-24)

The present study was undertaken to evaluate the impact of various combinations of nonionic surfactants on self-nanoemulsifying performance of two grades of Lauroglycol (Lauroglycol-90 and Lauroglycol-FCC) in glibenclamide (GBN) nanoemulsion. Formulations (L1-L30) were prepared by spontaneous emulsification method. Prepared formulations

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件